One More Technique For TRIB1

Statistical analysis All data were presented as count and percentage for discrete variables. The clinical parameters were compared between ERCC1 groups by using the chi-square test or the Fisher exact test, as appropriate. The DFS was analyzed by using the Kaplan-Meier method with the log-rank test. A Cox proportional hazard model with stepwise selection was conducted to identify risk factors for DFS. P-values of ON1910 Inc., Cary, NC, USA). RESULTS Clinical parameters correlated with ERCC1 expression The demographic details according to the ERCC1 expression investigated in this study are shown in Table 1. ERCC1-positive expression was detected in 104 patients (ERCC1-positive group), but 62 patients had ERCC1-negative tumors (ERCC1-negative group). The median follow-up time at the time of this analysis was 38.87 months. No significant differences in sex, T stage, N stage, histological differentiation, lymphovascular invasion, neural invasion, or postoperative CEA levels were observed between the two groups. However, ERCC1-positive ZD6474 in vitro expression was statistically significant in older patients (P = 0.031). Although not statistically significant, ERCC1 expression exhibited a tendency to be elevated in patients with preoperative high CEA levels (P = 0.095) (Table 1). Table 1 Clinical parameters correlated with ERCC1 expression In TRIB1 both groups, stage T3 tumors (88.55%) were the most common. Among all patients, stage III tumors (81.93%) were more common than stage II tumors (18.07%). In both groups, moderately differentiated tumors (87.95%) were the most common. On histopathological examination, lymphovascular invasion was seen in 55 (52.88%) and 34 patients (54.84%) in the ERCCI-negative and the ERCC1-positive groups, respectively (Table 1). Analysis of DFS and prognostic factors The 5-year DFS rate was 66.38% in the ERCC1-negative group and 71.16% in the ERCC1-positive group (P = 0.396) (Fig. 2). The 5-year DFS rate for patients with stage III disease was not significantly different between the two groups (64.85% in the negative group and 67.50% in the positive group, P = 0.582) (Fig. 3). The 5-year DFS rate was not significantly associated with the ERCC1 expression in all patients or in those with stage III disease. According to the univariate analysis, the prognostic factors for DFS were female sex (P = 0.047), N stage (P = 0.002), elevated preoperative CEA level (P = 0.008), and elevated postoperative CEA level (P